The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRVS | +2.93% | +112.35% | +16.24% | -38% |
| S&P | +13.19% | +87.83% | +13.42% | +231% |
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | -40.0% |
| Market Cap | $549.17M | 66.3% |
| Market Cap / Employee | $17.72M | 0.0% |
| Employees | 31 | 10.7% |
| Net Income | -$10.16M | 74.7% |
| EBITDA | -$10.54M | -45.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.87M | -38.7% |
| Accounts Receivable | $0.03M | -54.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.63M | 0.0% |
| Short Term Debt | $0.38M | 7.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -21.65% | 81.0% |
| Return On Invested Capital | -75.83% | -24.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.57M | -51.3% |
| Operating Free Cash Flow | -$9.57M | -51.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 26.98 | 6.63 | 5.53 | 6.85 | 6.17% |
| Price to Tangible Book Value | 26.98 | 6.63 | 5.53 | 6.85 | 6.17% |
| Enterprise Value to EBITDA | -38.94 | -19.79 | -23.24 | -51.77 | 20.47% |
| Return on Equity | -174.9% | -100.1% | -68.7% | -35.8% | -82.13% |
| Total Debt | $1.12M | $1.15M | $1.08M | $1.01M | 185.59% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
